Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK111 in Active Ankylosing Spondylitis
NCT06378697Phase 3Completed
- Sponsor
- Akeso, Inc.
- Start
- Nov 2023
- Primary completion
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of gumokimab in ankylosing spondylitis (AS), sponsored by Akeso, Inc.. Started Nov 2023; status: completed.
02
Drugs
gumokimab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT06378697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06378697.